The genetic polymorphism with an isoleucine-to-methionine substitution at position 148 (rs738409 C>G) in the patatin-like phospholipase domain protein 3 (PNPLA3 ) gene confers risk of steatosis. PNPLA3 polymorphism is shown to be associated with alcoholic liver disease (ALD). We performed a systematic review and meta-analysis to examine association of this genetic polymorphism with ALD spectrum and its severity.
INTRODUCTION
Alcohol abuse is a common cause of cirrhosis and indication for liver transplantation. Clinical spectrum of alcohol-related liver disease includes simple steatosis or alcoholic fatty liver (AFL), alcoholic liver injury with elevated transaminases but without cirrhosis (ALI), alcoholic cirrhosis (AC), and hepatocellular carcinoma (HCC). Amount of alcohol consumption is the most important factor in the development of ALI and AC ( 1 ) . However, only ∼ 10-20% of heavy drinkers develop AC, suggesting a role of other host factors and comorbidities predisposing to ALI and its progression to AC and HCC ( 2 ) . Data on genetic predisposition to alcoholism and alcoholic liver disease (ALD) among monozygotic twins ( 3 ) , and on ethnic variations on ALD-related mortality independent of amount of alcohol use, support the role of genetic factors in mediating ALD (4) (5) (6) . Single-nucleotide polymorphisms within genes of cytokines, alcohol-metabolizing enzymes, and antioxidant enzymes have been shown to be associated with progression of alcohol-induced liver fi brosis ( 7 ) . However, data on association of these genetic factors in the development of ALD have remained confl icting until a few years ago ( 8 ) .
Recently, a genome-wide screen in a population of Hispanic, African, and European Americans from the Dallas Heart Study identifi ed a strong association between a single-nucleotide polymorphism, rs738409 C>G (causing an isoleucine-to-methionine substitution at position 148, I148M), in the patatin-like phospholipase domain containing protein 3 ( PNPLA3 ) gene and hepatic fat content ( 9 ) . In addition, a strong association between PNPLA3 genotype and elevated alanine aminotransferase levels as well as hepatic fat content was confi rmed in other populations (10) (11) (12) (13) (14) (15) (16) . Although this gene was discovered to be associated with steatosis in patients with nonalcoholic fatty liver disease ( 12 ) , data are emerging on its association with other liver diseases, including hepatitis C virus cirrhosis ( 17 ) and alcoholic cirrhosis ( 18 ) . We performed a systematic review and meta-analysis of studies to examine the association between the presence of the PNPLA3 rs738409 polymorphism and the spectrum of ALD.
METHODS

Identifi cation and retrieval of primary studies
We performed search of PubMed/Medline, Embase, and Cochrane for full-length articles in English examining PNPLA3 polymorphism association among ALD patients. We followed the MOOSE (Meta-analysis of Observational Studies in Epidemiology) guidelines ( 19 ) . Th e initial medical subject heading search terms were "liver cirrhosis, alcoholic, " and "adiponutrin, human" and expanded search using "rs738409" and "patatin-like phospholipase domain-containing 3 protein, human. " All databases were searched from their inception through September 2014. Articles were selected for full text review based on title and abstract. Manual search of the bibliographies of retrieved publications was done by two independent investigators (H.S. and A.K.S.) to increase yield of potentially relevant articles.
Inclusion and exclusion criteria
Inclusion and exclusion criteria were defi ned at the time of study conception and before data collection. For inclusion into the meta-analysis, a study had to (i) include patients with alcohol dependence; (ii) assess the presence of the PNPLA3 variant (rs738409 C>G); (iii) defi ne the ALD spectrum to AFL: steatosis on liver ultrasound in the absence of elevated liver enzymes, ALI: liver steatosis accompanied by elevated amino transferases in the absence of cirrhosis, AC: confi rmed by biopsy or clinical evaluation supported by hematological, biochemical, and/or radiologic imaging fi ndings, and HCC: diagnostic fi ndings on triple phase magnetic resonance imaging or computed tomography or on histological examination of the liver tissue; and (iv) be published as a full-length article. We excluded studies (i) without gene frequency and/or odds ratio (OR) data and (ii) including subjects with other liver disease etiologies without separate data among ALD patients.
Study selection and data extraction
Two reviewers (H.S. and A.K.S.) independently examined the studies for the inclusion and exclusion criteria and also extracted the data from the studies included in the analysis. Th e reviewers resolved discrepancies by jointly reviewing the study in question. Studies included in the analysis were reviewed for (i) study characteristics: author and year of publication, and study design (population based or not, using controls or not); (ii) study population: ALD spectrum and the sample sizes; (iii) frequencies of PNPLA3 polymorphism genotypes (rs738409 CC, CG, and GG): among healthy controls and ALD patients; and (iv) ORs: for association of PNPLA3 polymorphism and spectrum of ALD and for severity of ALD among diseased drinkers. Corresponding authors of studies included in the analysis were contacted to obtain the individual participant data.
End points and outcomes
Our study end points were (i) alcohol-related fatty liver (FL), ALI, AC, or HCC among drinkers compared with healthy controls and (ii) severity of ALD among drinkers. Healthy controls were defi ned as subjects without evidence of AFL, ALI, AC, or HCC irrespective of their drinking status as our primary aim was to examine the association of PNPLA3 polymorphisms with the predisposition to ALD.
We also performed the subgroup analyses for patient demographics (age, gender, and ethnicity) using the individual participant data.
Assessment of study quality
Th e quality of included studies was assessed independently by two authors (H.S. and A.K.S.) using the Newcastle-Ottawa Quality Assessment Scale for case-control studies ( 20 ) . Th is scale has two diff erent instruments for assessing case-control and cohort studies. Each instrument includes measures of quality in three domains: selection, comparability, and exposure. A study can receive up to one point for each of four areas meas- ured within the selection domain and for each of three areas measured within the exposure domain. A maximum of two points can be assigned within the comparability domain. Th e highest possible score is nine. High-quality studies were considered to have a score of seven or greater. Any discrepancies between the two authors were addressed by a joint reevaluation of the original article.
We also assessed the Hardy-Weinberg equilibrium (HWE) to assess genotype frequencies in the included studies. As the deviation from HWE in controls has been associated with problems in the design and conduct of genetic association studies particularly because of population stratifi cation, genotyping error, or selection bias ( 21, 22 ) , the magnitude of deviations from HWE and its statistical signifi cance are reported. HWE analysis was performed among the healthy controls using the χ 2 test (χ 2 value <3.84 indicating allele frequency to be in HWE). If a study showed a signifi cant deviation of HWE, we planned to perform sensitivity analyses excluding the studies which deviated from HWE (if any) as recommended ( 23 ) .
Statistical analysis
Th e strength of the association between rs738409 and ALD prevalence was expressed by OR and their corresponding 95% confi dence interval. Random eff ects model was used for analyzing the pooled data for all the analyses ( 24 ) . Heterogeneity was measured by the between-study variance using the I 2 statistics ( 25 ) with a cutoff of ≥50% and χ 2 test with P <0.10 ( 25 ). When there was heterogeneity with only two studies in the analysis, we reviewed both the studies for any diff erences to explain the heterogeneity. For heterogeneous data on analysis with more than two studies, we took stepwise approach: (i) excluding study with diff erent ethnicity on Mestizio subjects, (ii) excluding two studies with highest and lowest OR, and (iii) meta-regression if needed. To assess the extent of publication bias, both Egger's test and the Begg and Mazumdar's test were used on unadjusted analyses ( 26, 27 ) . Funnel plots were assessed by two independent investigators (H.S. and A.K.S.). At least two studies in the analyses were needed to examine the heterogeneity and three studies for examining any publication bias.
To examine independent association of rs738409 and ALD spectrum, generalized linear mixed models were built for patient demographics using the individual participant data. Th is statistical method was chosen to take into account the diff erences between the studies and is equivalent to the random eff ects model used for our main analysis. Data were not controlled for body mass index, given that only two of the fi ve studies had information on this variable. First unadjusted odds for a particular outcome were assessed comparing the various PNPLA3 polymorphisms. Th en, in a stepwise manner age and gender were entered into the model to examine independent association of PNPLA3 polymorphisms as well as individual demographics on the outcome. All statistical analyses were performed using the Comprehensive Meta-analysis soft ware (Biostat, Englewood, NJ).
RESULTS
Baseline study characteristics
A total of 254 citations were retrieved on initial search. Aft er reviewing article titles and abstracts, a total of 14 studies were included for full-text review ( Figure 1 ). Of these, four studies (28) (29) (30) (31) were excluded because of unavailability of data for analysis and/or were not full manuscripts, leaving 10 studies involving 4,112 patients for this meta-analysis. All 10 studies reported PNPLA3 polymorphism data on AC, 4 studies each on ALI and HCC, whereas only one study reported data on AFL ( Table 1 ) . Of the 10 studies, 7 recruited healthy controls ( 18, (32) (33) (34) (35) (36) (37) , whereas the other 3 had no control group (38) (39) (40) . Healthy controls were heavy drinkers without liver disease in two studies ( 18, 32 ) , or nondrinkers without liver disease in four studies ( 33, 34, 36, 37 ) . One study included both drinkers and nondrinkers without liver disease ( 35 ) . Th e baseline characteristics of the included studies are reported in Table 1 . All studies included subjects with Caucasian ethnicity except one study that included Mestizio subjects, people from Mexico with mixed European and Native American ancestry ( 32 ) .
Assessment of study quality
Based on the Newcastle-Ottawa Scale, half of the included studies (fi ve) were considered as high-quality studies ( Supplementary  Table S1 online). In addition, all seven studies reporting genotype frequencies for control population were in HWE ( Supplementary  Table S2 ).
PNPLA3 polymorphism (rs738409) in ALD compared with healthy controls
A total of 7 studies involving 2,878 ALD patients and 4,091 controls were analyzed. Compared with healthy controls, prevalence of the PNPLA3 polymorphism rs738409 was assessed in patients ( Figure 2d ). Data were homogeneous ( I 2 =35.43%, P =0.21). Similar OR for the rs738409 GG with AFL (1 study), ALI (3 studies), AC (7 studies), and HCC (2 studies).
Alcoholic fatty liver . Th e OR of the rs738409 CG and GG genotypes as compared with CC genotype in AFL was similar to controls when data were pooled from population-based and multicenter samples in one study ( 35 ) : 0.74 (0.54-1.03) and 0.62 (0.13-2.93), respectively ( Figures 2a and 3a ) . Th e data were homogeneous for both analyses with respective values of I 2 =0%, P =0.69 and I 2 =45.98%, P =0.17.
Alcoholic liver injury . Th e OR of rs738409 CG genotype compared with CC genotype was 1.45 (1.24-1.69) on comparing patients with ALI with healthy controls ( Figure 2b ). Data were homogeneous ( I 2 =0%, P =0.995) without any publication bias as assessed by Egger's test ( P =0.569) or Begg and Mazumdar's test ( P =0.5). Similar OR for the rs738409 GG genotype was 2.22 (1.50-3.28) as compared with healthy controls ( Figure 3b ) Figure 3d ).
PNPLA3 polymorphism (rs738409) and severity of alcoholic liver disease
A total of 8 studies involving 3,711 ALD patients were pooled for these analyses ( Figure 4a-e ( Figure 4b ) . Th e data were heterogeneous ( I 2 =76%, P =0.039). Diff erences on proportion of patients with AC in the two studies included in this analysis, ∼ 80% in one study ( 33 ) and only 22% in the other study ( 40 ) , probably explains this heterogeneity. Publication bias could not be done with only two studies in this analysis. In addition, OR of rs738409 GG genotype compared with CG genotype was 2.90 (1.53-5.49) in one study ( 40 Individual participant data analyses . Individual participant data were obtained on 2,033 ALD patients (734 ALI; 1,153 AC without HCC; and 146 AC with HCC) from 5 studies ( Table 2 ) . Data on 487 healthy controls (drinkers with normal blood tests) heterogeneity ( I 2 =20.37%, P =0.26). OR of rs738409 GG vs. CG genotype was 2.10 (1.22-3.63) with homogeneous data ( I 2 =0%, P =0.912; Figure 4e ).
Subgroup analyses
Ethnicity analysis . Aft er excluding the study recruiting Mestizo population ( 32 ) , pooled eff ect size remained in the same direction on the outcomes including this study ( Figures 2b,c and 4a ) Generalized linear mixed model analysis on the individual participant data showed unadjusted OR for AC vs. ALI comparing CG with CC, GG with CC, and GG with CG to be 1.9 (1.3-2.9), 3.0 (2.0-4.6), and 1.6 (1.1-2.3), respectively. Aft er adding age and gender into the model in a stepwise manner, the signifi cance of the OR remained unchanged and in the same direction ( Table 3 ). Participant age but not the gender independently predicted development of cirrhosis ( Table 3 ). Similar unadjusted OR on the development of HCC among AC patients was 1.5 (0.5-2.6), 2.9 (0.8-11.1), and 2.1 (0.1-68.1), respectively. Th e data for HCC remained signifi cant with wide confi dence interval probably because of small sample size, with data on HCC available on only 358 patients from two studies.
DISCUSSION
Th e current meta-analysis demonstrates several important fi ndings on the association of the PNPLA3 gene polymorphisms with ALD. Compared with controls, prevalence of PNPLA3 polymorphisms was higher among patients with ALI, AC, and HCC in AC. Furthermore, the prevalence of these polymorphisms was higher among patients with AC compared with those with ALI or AFL and among AC patients with HCC compared with those without HCC. Data on prevalence of PNPLA3 polymorphisms were similar when drinkers with FL were compared with controls. Individual participant data also confi rmed these observations. Th e disease spectrum in both alcoholic and nonalcoholic fatty liver disease is similar and starts with fatty liver change followed by infl ammation, fi brosis, and fi nally cirrhosis. Hepatic steatosis is seen in 90% of heavy alcohol drinkers and is usually macrovesicular (41) (42) (43) . Fatty infi ltration develops rapidly within 2 weeks and resolves with abstinence ( 44, 45 ) . Th e similar polymorphism prevalence in drinkers with AFL and controls, as found in the current meta-analysis, blends well with the fact that AFL is a universal phenomenon in alcoholics and is reversible on abstinence. However, this is not true for ALI, AC, and HCC.
Stickel et al. ( 7 ) have reviewed previous studies on alcoholic dehydrogenase gene polymorphism in alcoholic patients and showed that results were inconsistent. Th e available data do not provide clear evidence that demonstrates a contribution of alcohol metabolism (alcohol dehydrogenase), antioxidant enzymes (CYP2E1, GSTM1, MnSOD), or cytokines (interleukin and tumor necrosis factors) genotype polymorphisms to the development of ALD ( 7 ). PNPLA3 is the fi rst genetic marker that was confi rmed by repeated studies to predispose to ALD and is associated with worse severity as we showed in the current meta-analysis.
Two recent meta-analyses have shown association of PNPLA3 with advanced fi brosis ( 46, 47 ) . Heterogeneous data due to inclusion of patients with various liver disease etiologies was a limitation in one study ( 46 ) . Furthermore, this study included only three studies on alcoholic liver disease ( 29, 33, 35 ) in comparison with fi ve studies in our current analysis ( 18, (32) (33) (34) (35) . Our meta-analysis provides pooled data comparing ALD patients with healthy controls on the association of PNPLA3 polymorphisms with HCC in two studies ( 34, 36 ) and AC in four studies ( 34, 36, 38, 39 ) . Furthermore, we also examine the association of the remaining spectrum of ALD and PNPLA3 polymorphisms including FL and ALI. Our study fi ndings on the risk of fi brosis and AC are similar to the second meta-analysis except for lower OR for the GG genotype. Th is may be as this analysis included three citations published as abstracts ( 29-31 ) that were not included in our current analysis.
In another meta-analysis, PNPLA3 polymorphisms among cirrhotics have been associated with HCC ( 48 ) . Our meta-analysis in addition to confi rming the fi ndings from this study also examines the HCC risk in alcoholics compared with healthy controls. Furthermore, we also examined the association of PNPLA3 polymorphisms with the other spectrum of ALD. Our analysis may be limited by the possibility of publication bias. In order to minimize this possibility and subsequently overestimation of the true eff ect size because of negative study identification failure ( 49 ), we combined searches from PubMed/Medline, Embase, and Cochrane with manual searches. Although we used procedures in agreement with current guidelines, we cannot formally rule out the possibility that we missed studies that were not accessible ( 49 ) . Another limitation of this meta-analysis is the inclusion of case-control studies in which the potential for biases (e.g., selection and reporting) is higher when compared with randomized trials and they are more inherent to confounding factors. In the current analysis, the rs738409 genotype frequencies in the control group that followed the HWE is a strength of this study as sampling bias or coincidental gene association because of population stratifi cation could be excluded ( 39 ), but some authors have shown that HWE testing is not a reliable way of detecting genotyping error and can certainly not exclude population stratifi cation ( 21, 50 ) . Finally, we were not able to retrieve all the individual participant data (only 46% of all individual participant data were obtained) from the included studies, especially the largest one by Stickel et al. ( 35 ) (1,419 patients). Th erefore, we used the individual participant data for only the subgroup analyses and not our main outcome analyses.
In conclusion, the PNPLA3 rs738409 polymorphism is associated with increased risk for the entire spectrum of ALD among drinkers, and increased propensity for AC and HCC in ALI patients. Studies are needed to clarify the association of PNPLA3 and steatosis in alcohol drinkers. Th e PNPLA3 gene may potentially be a therapeutic target in ALD and in the selection of donor organs for transplantation of patients with ALD.
